Company intelligence / Profile preview
Liaoning Green Biological Pharmaceutical Group
Shenyang, Liaoning, Chinasygreen.com.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Liaoning Green Biological Pharmaceutical Group develops small molecule drugs with a focus on urogenital diseases and related indications. Its lead asset, PE‑001, has reached Phase 2 clinical trials for premature ejaculation. Another candidate, MT‑1207, has been evaluated in early-stage clinical studies for hypertension to assess tolerability and pharmacokinetics. The company appears to have at least two active programs in its pipeline as of June 2025[1].
- Therapeutic areas
- CardiovascularNephrologyMen's Health
- Modalities
- Small molecule drug
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
China Pharmaceutical University (originator organization for PE‑001)[1]
Beyond the preview
Go deeper on Liaoning Green Biological Pharmaceutical Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Liaoning Green Biological Pharmaceutical Group.